Efficacy and Safety of Tacrolimus Vs Cyclophosphamide in the Therapy of Patients with Idiopathic Membranous Nephropathy: a Meta-analysis

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2019 Jul 17

PMID 31308629

Citations 10

Authors

Wenshan Lin

Hong-Yan Li

Shujun Lin

Tianbiao Zhou

Affiliations

Soon will be listed here.

Abstract

Background: As one of the therapeutic drugs for idiopathic membranous nephropathy (IMN), tacrolimus (TAC) has not been fully vindicated for its efficacy and tolerability. A meta-analysis was performed to detect the efficacy and safety of TAC plus glucocorticoid vs cyclophosphamide (CTX) plus glucocorticoid in therapy of patients with IMN.

Methods: A literature search with a pre-defined search strategy was conducted using English databases (PubMed, EMBASE, ClinicalKey and the Cochrane Library) and Chinese databases (China National Knowledge International, Wanfang, Chinese Scientific Journal Database (VIP)) from inception to Nov 19, 2018. Any high-quality randomized controlled trials (RCTs) comparing the effectiveness or safety of TAC with CTX in IMN patients were included. Data were extracted by two authors independently and analyzed using RevMan 5.3.

Results: Four randomized controlled studies were included. In this analysis, we did not find that the statistically significant difference between TAC and CTX groups on 6-month and 12-month treatment complete remission (CR) was evident (6-month: OR=1.53, 95% CI: 0.85-2.76, =0.15; 12-month: OR=2.17, 95% CI: 0.56-8.44, =0.27). But TAC had better 6-month total remission (TR; total CR plus partial remission [PR]) than CTX (6-month: OR=2.62, 95% CI: 1.38-4.96, =0.003; 12-month: OR=1.74, 95% CI: 0.29-10.48, =0.54), and got a lower proteinuria after 6-month treatment (OR=-0.80, 95% CI: -1.53 to -0.07, =0.03). TAC had a lower incidence rate on leucopenia than CTX, but had a tendency towards higher blood creatinine. In the meantime, tremor in TAC group was higher than that in CTX group. The differences on other adverse effects such as gastrointestinal syndrome, infection, herpes zoster, hypertension, liver function disorder and hyperglycemia were also analyzed. However, none of them were statistically significant.

Conclusion: TAC treatment could get high value of TR and had low value of proteinuria level when compared with those in CTX on 6-month treatment in therapy of patients with IMN.

Citing Articles

Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series.

Sun L, Chen F, Zhang X Clin Case Rep. 2024; 12(11):e9553.

PMID: 39512788 PMC: 11540803. DOI: 10.1002/ccr3.9553.

Efficacy of tacrolimus monotherapy in primary membranous nephropathy.

Zhang Y, Ran L, Guo L, Gou Y, Guo S, Xu Y Open Med (Wars). 2024; 19(1):20240957.

PMID: 38841175 PMC: 11151391. DOI: 10.1515/med-2024-0957.

Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy.

Xing H, Ma D, Li J, Xu Q, Ji L, Zhu Q Front Pharmacol. 2024; 15:1286422.

PMID: 38420195 PMC: 10899500. DOI: 10.3389/fphar.2024.1286422.

Case report: Successful treatment of refractory membranous nephropathy with telitacicept.

Zhang L, Jin H, Wang D, Wang Y Front Immunol. 2023; 14:1268929.

PMID: 37915584 PMC: 10616774. DOI: 10.3389/fimmu.2023.1268929.

Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report.

Wang J, Sun Y, Kang Z, Zhang S, Yu C, Zhang W World J Clin Cases. 2023; 11(22):5309-5315.

PMID: 37621578 PMC: 10445080. DOI: 10.12998/wjcc.v11.i22.5309.

References

Wasserstein A . Membranous glomerulonephritis. J Am Soc Nephrol. 1997; 8(4):664-74. DOI: 10.1681/ASN.V84664. View

Cattran D, Appel G, Hebert L, Hunsicker L, Pohl M, Hoy W . Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59(4):1484-90. DOI: 10.1046/j.1523-1755.2001.0590041484.x. View

McCauley J, Tzakis A, Fung J, Todo S, Starzl T . FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet. 1990; 335(8690):674. DOI: 10.1016/0140-6736(90)90471-g. View

Praga M, Barrio V, Juarez G, Luno J . Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007; 71(9):924-30. DOI: 10.1038/sj.ki.5002215. View

Westhoff T, van der Giet M . Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs. 2007; 16(7):1099-110. DOI: 10.1517/13543784.16.7.1099. View

Chen M, Li H, Li X, Lu F, Ni Z, Xu F . Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3):233-8. DOI: 10.1097/MAJ.0b013e3181ca3a7d. View

He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F . Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 2012; 26(3):564-71. DOI: 10.5301/jn.5000199. View

Debiec H, Ronco P . Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol. 2014; 36(4):381-97. DOI: 10.1007/s00281-014-0423-y. View

. Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl (2011). 2014; 2(2):186-197. PMC: 4089709. DOI: 10.1038/kisup.2012.20. View

10.

Santosh T, Liu H, Liu B . Effect of tacrolimus in idiopathic membranous nephropathy: a meta-analysis. Chin Med J (Engl). 2014; 127(14):2693-9. View

11.

Thompson A, Cattran D, Blank M, Nachman P . Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol. 2015; 26(12):2930-7. PMC: 4657845. DOI: 10.1681/ASN.2015010091. View

12.

Ramachandran R, Hn H, Kumar V, Nada R, Yadav A, Goyal A . Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton). 2015; 21(2):139-46. DOI: 10.1111/nep.12569. View

13.

Li Z, Hu M, Zhang C, Wang Y . Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015; 35(5):623-628. DOI: 10.1007/s11596-015-1480-8. View

14.

Shen X, Jiang H, Ying M, Xie Z, Li X, Wang H . Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep. 2016; 6:32087. PMC: 5007516. DOI: 10.1038/srep32087. View

15.

Zhu L, Liu L, Yao L, Wang L . Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. Drugs. 2017; 77(2):187-199. DOI: 10.1007/s40265-016-0683-z. View

16.

Ramachandran R, Yadav A, Kumar V, Siva Tez Pinnamaneni V, Nada R, Ghosh R . Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide. Kidney Int Rep. 2017; 2(4):610-616. PMC: 5678834. DOI: 10.1016/j.ekir.2017.02.004. View

17.

Ponticelli C, Escoli R, Moroni G . Does cyclophosphamide still play a role in glomerular diseases?. Autoimmun Rev. 2018; 17(10):1022-1027. DOI: 10.1016/j.autrev.2018.04.007. View